Drugs / JBI-802
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07612280 | Oct 2024 → Jun 2028 expected | essential thrombocythemia, myelodysplastic/myeloproliferative neoplasm | Jubilant Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05268666 | Apr 2022 → Dec 2024 | metastatic neoplasm | Jubilant Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07207395 | Apr 2025 → Oct 2027 expected | non-small cell lung carcinoma | The Christ Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | Jubilant Therapeutics Inc. | Results JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis jubilanttx.com ↗
Jubilant Therapeutics Inc ., a clinical-stage biotechnology company pioneering the development of a first-in-class CoREST (Co-repressor of Repressor Element-1 Silencing Transcription) inhibitor JBI-802 with the dual activity on LSD1 and HDAC6, today announced preliminary safety, pharmacokinetic and initial efficacy results of the Phase I trial in advanced cancer patients. |
| 2023-01-05 | Jubilant Therapeutics Inc. | Regulatory Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC) jubilanttx.com ↗
today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation for JBI-802 for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML). |
| 2022-01-05 | Jubilant Therapeutics Inc. | Regulatory Jubilant Therapeutics Announces FDA Clearance of IND for JBI-802, a Novel Dual LSD1 and HDAC6 Inhibitor, for treatment of Solid Tumors jubilanttx.com ↗
Jubilant Therapeutics Inc, a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of the investigational new drug application (IND) for JBI-802, a novel, oral, potent and selective dual inhibitor of LSD1 and HDAC6, for the treatment of small cell lung cancer (SCLC), treatment-induced neuro-endocrine prostate cancer (NEPC) and other mutation-defined neuroendocrine tumors. |
| 2020-12-07 | Jubilant Therapeutics Inc. | Results Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers jubilanttx.com ↗
Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced efficacy data from a study of JBI-802, its novel dual inhibitor of LSD1-HDAC6, in multiple acute myeloid leukemia (AML) models, and the identification of novel, undisclosed biomarkers that will aid in patient stratification. |
| 2020-06-22 | Jubilant Therapeutics Inc. | Results Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research, Reveals Unique Dual-Action Anti-Cancer Mechanism Underscoring First-in-Class Pipeline Asset in Hematological Tumors jubilanttx.com ↗
The preclinical data demonstrated that JBI-802 has strong efficacy in multiple in vivo cancer models mediated by LSD1 and HDAC6 inhibition, while demonstrating excellent selectivity against other HDACs and superior in vivo efficacy compared to single agents targeting LSD1 or HDAC6. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JBI-802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07207395 ↗ |
| Action | Inhibit | “LSD1/HDAC6 inhibitor” NCT05268666 ↗ |
| Modality | Small molecule | — CHEMBL5316158 ↗ |
| Route | Oral | “10 mg orally once daily” NCT05268666 ↗ |
| Target | HDAC6 | “LSD1/HDAC6 Inhibitor” NCT07207395 ↗ |